Objective: To investigate the recurrence and severity of climacteric symptoms after two methods of discontinuation of prolonged hormone therapy.
T he Women`s Health Initiative (WHI) study reported that the risks associated with specific regimens of hormone therapy (HT) in specific populations outweigh the benefits. 1, 2 Moreover, the association between breast cancer and prolonged duration of HT has long been established. 1<5 These findings created an atmosphere that urged patients to discontinue HT. 6, 7 However, there are no clear guidelines in the literature regarding the preferred method of discontinuation. No data exist regarding whether abrupt discontinuation of HT is associated with a higher risk of recurrence of climacteric symptoms, compared with gradual discontinuation. In the absence of adequate data, there is no consensus on this issue. Two options were suggested by The North American Menopause Society (NAMS) panelists for HT discontinuation: i) abrupt cessation, entitled Bcold turkey^; and ii) tapering therapy by either skipping progressively more days between doses or lowering doses every 4 to 6 weeks. 8 The aim of this study was to compare two methods for HT discontinuation after prolonged use: abrupt cessation versus gradually tapering therapy. Clarification of the preferred method of discontinuation of treatment will enable treating physicians to advise patients to discontinue therapy with minimal disruption to their quality of life.
METHODS

Study participants
From May 2001 to April 2003, a total of 91 healthy postmenopausal women opting to discontinue therapy were voluntarily enrolled into the study. All women were treated with combined estrogen-progestin therapy or estrogen-alone therapy for more than 3 years. None had received either concomitant medication or overthe-counter supplementation that could affect their evaluation during the study. Women with the following conditions were excluded from the trial: smoking, alcoholism, severe liver or kidney disorders, active ischemic heart disease, evidence of acute thrombosis and infectious diseases, abnormal Pap smear, vaginal bleeding of undiagnosed cause, endometrial hyperplasia, severe uncontrolled hypertension. An informed consent was obtained from all women.
Experimental design
This was a prospective, nonblinded, randomized study conducted in a menopause clinic setting at a university hospital and affiliated clinics. Study-eligible women were randomly assigned to two treatment groups. HT was discontinued either abruptly or gradually. Gradual discontinuation entailed reducing the dose by one tablet per week per month, so that complete cessation took place after 6 months. Therefore, by 6 months both groups were off HT.
To determine the appropriate sample size, we assumed a power of 90%, an alpha level of 0.05, and a return to HT in the abrupt and gradual discontinuation groups of 40% and 15%, respectively; with these assumptions, a sample size of 100 women was needed.
In the absence of data in the literature, the assumptions regarding the incidence of return to HT in each group were based on clinical impression only. Randomization assumed Bernoulli distribution with probability of 0.5 for each woman to join the abrupt group. After running a randomization with SAS 8e package, 54 women were assigned to the abrupt group (group 1) and 46 to the gradual discontinuation group (group 2). Nine women were excluded after randomization to the groups because of predetermined exclusion criteria. This left us with 50 women in group 1 and 41 participants in group 2.
Symptoms and compliance were monitored with the Greene scale, a standard climacteric scale. 9 This scale distinguishes 21 different symptoms clustered into four subclasses: 11 psychological symptoms (subdivided into 6 anxiety symptoms and 5 depression symptoms), 7 somatic symptoms (eg, headaches, muscle and joint pain), 2 vasomotor symptoms (hot flushes and night sweats), and a sexual symptom (loss of sexual interest). Each symptom score ranges from 0 (Bnot at all^) to 3 (Bquite a bit^), compiling a Greene score range of 0 to 63. The questionnaire of the Greene climacteric scale was completed at 1, 3, 6, 9, and 12 months by the caring physician at the patient`s visits and by a telephone questionnaire. The telephone questionnaire was conducted by a single, nonphysician, highly trained interviewer.
Statistical methods
Data analysis was performed using SAS 8e software. For all continuous variables, summary statistics were presented, including mean and standard error of the mean (SEM). The nonparametric Wilcoxon test (Mann-Whitney test) and the two-sample t test were performed. Pearson`s W 2 was used to compare discrete variables. Survival analysis was conducted to follow the resumption of HT using the Kaplan-Meier method and log-rank test for statistical significance. Statistical significance was inferred at P e 0.05.
RESULTS
Study population
Ninety-one white women aged 48 to 73 years (mean age 56.8 T 4.2 years) participated in the study. The mean HT duration was 8.8 T 3.8 years. Fifty patients were assigned to the abrupt discontinuation group (group 1) and 41 to the gradual discontinuation group (group 2). No differences were noted in individual characteristics between the two groups regarding age at menopause, body mass index, type of regimen, and reasons cited to either start or discontinue HT. About half of the women in each group cited hot flushes as the reason HT was started. The severity of hot flushes was subjectively defined by each interviewee. Women in group 1 (57.96 T 0.69 years) were slightly but significantly older than women in group 2 (55.13 T 0.76 years) (P = 0.008); however, the difference in the median age between group 1 and group 2 (57 vs 56 years, respectively) was insignificant (P = 0.08). Age at menopause and HT duration was similar in both groups ( Table 1) .
Side effects of HT discontinuation
Vaginal bleeding upon HT discontinuation was rare (3%) in the whole study group (N = 91) during 12 months of follow-up, and did not differ between groups after HT discontinuation ( Table 2 ). Dyspareunia due to vaginal dryness and weight gain (more than 1 kg per month) were reported by significantly more women 1 month after HT was abruptly stopped (P = 0.05 for both parameters). However, beyond a single month, there were no significant differences in dyspareunia and weight gain reported by women in either group (Tables 3 and 4 ).
Menopause symptoms after HT discontinuation
Half of the women in each group had started HT because of vasomotor symptoms (54% in group 1 and 53.5% in group 2). All women were free of climacteric symptomatology while using HT. Comparable percentage of patients in both groups resumed HT due to vasomotor symptoms. Twenty-one patients (42%) in group 1 and 15 patients (36.6%) in group 2 returned to HT within 9 months; however, in group 1 HT resumed during the first 3 months, whereas in group 2 HT resumed mostly between 3 and 6 months ( Fig.1 ). Although the probability of staying off HT was slightly higher in group 2 during the entire study period, statistical significance could not be achieved (P = 0.67). The overall success of staying off HT after 1 year was comparable in both groups (Fig. 2 ). During the study period, the Greene score ranged from 0 to 50. During the first 3 months after HT discontinuation, the total Greene scale score differed significantly between the groups (P = 0.001 and 0.047 at 1 and 3 months, respectively), but this difference disappeared after 6 months (Fig. 3 ). The total Greene score at 6 months after gradual discontinuation of HT, when women were completely off HT, was similar to that observed at 1 month in the abrupt HT cessation group (16 versus 17.7, P = 0.246).
Specifically, mood disturbances and somatic symptomatology were significantly worse in group 1, a month after HT withdrawal (P = 0.049 and 0.022, respectively; Figs. 4 and 5). However, by 3 months no significant differences could be recorded between groups. During the first 3 months after HT discontinuation, women in group 1 experienced significantly more severe vasomotor symptoms than did those in group 2 (P = 0.0001 and 0.001 at 1 and 3 months, respectively; Fig. 6 ). Interestingly, 6 months after HT discontinuation, a switch of this trend was observed, where the severity of hot flushes and night sweats was significantly higher in group 2 than in group 1 (4.31 versus 2.57 respectively, P = 0.001; Fig. 6 ). Moreover, the vasomotor score at 6 and 9 months after gradual discontinuation of HT, when women were completely off HT for 1 and 3 months, was similar to that observed at 1 and 3 months in the abrupt HT cessation group (4.31 and 3.75 versus 3.42 and 3.33, P = 0.073 and 0.24, respectively; Fig. 6 ). With gradual discontinuation of HT, the vasomotor score slowly increased. Tapering HT for the first 3 months resulted in a moderate elevation of the vasomotor score (0.65 versus 1.74, P = 0.003). Continued tapering of HT for the next 3 months yielded a larger increase in the vasomotor score (1.74 versus 4.3, P G 0.0001; Fig. 6 ).
DISCUSSION
Hormone therapy is an effective mode of relieving climacteric symptoms, treating urogenital atrophy, and preventing osteoporosis. However, because of the recently published questionable risk/benefit ratio of prolonged HT in terms of cardiovascular and breast morbidity, many patients choose to abandon prolonged HT. The question of how long HT should be prescribed for symptom relief is unresolved by the current literature. The NAMS panelists recommended the guiding principal of prescribing the lowest effective dose of HT for the shortest time. Short-term HT was vaguely defined as 3 to 5 years, whereas long-term therapy was considered longer than 3 to 5 years. 8 To our knowledge, the preferred method of discontinuation of HT has never been investigated in a controlled randomized study. No data exist regarding whether abrupt discontinuation of HT is associated with a higher risk of recurrence of climacteric symptoms, compared with gradual discontinuation. Gradual cessation of HT could mean either Bdose tapering( progressively decreasing the daily dose of HT) or Bday tapering^(decreasing the number of days per week of HT use). 10 We used a specific regimen of gradual day tapering by lowering HT doses by one tablet per week per month, so that complete cessation took place after 6 months.
The underlying physiologic mechanisms of climacteric symptomatology are not completely understood. Estrogen withdrawal at menopause is clearly the precipitating factor, but the relationship that might exist between estrogen and the climacteric syndrome is still illusive. 11 The rapid decline in blood estrogen level may be responsible for the occurrence of vasomotor symptoms. The onset of more frequent and severe hot flushes after oophorectomy or after gonadotropin-releasing hormone analogue administration compared with after natural menopause supports this contention. 12 This observation was the basis of our hypothesis that a gradual decline in estrogen levels by a slow decrease in estrogen dose could lead to an adaptation effect and reduced reoccurrence of vasomotor symptoms once HT is stopped.
Our study group that was on prolonged HT (~8 years) has rarely been characterized. These women were healthy, nonobese women at their mid-50s who had been started on HT since the age of menopause (~47 years), mostly because of daily or nocturnal disturbing hot flushes (Table 1 ) and concern regarding their declining quality of life. Ettinger et al 7 reported that most postmenopausal HT users tried to abandon HT, despite not being well informed about the WHI findings. In this study the reasons for terminating HT were somewhat ambiguous: approximately 70% of the women cited the prolonged time of treatment as the only reason, and 25% to 46% expressed the fear of beast cancer as being the main reason. Of note is that erratic vaginal bleeding did not serve as a predominant reason to stop HT after prolonged use, FIG. 3 . The symptomatology profile (expressed by the Greene score) of women after HT discontinuation. During the first 3 months after HT discontinuation, the total Greene scale score differed significantly between groups (P = 0.001 and 0.047 at 1 and 3 months, respectively); however, this difference disappeared after 6 months. The Greene score at 1 month after abrupt cessation of HT was comparable to the Greene score 6 months after gradual HT discontinuation (16 versus 17.7, P = 0.246).
FIG. 6. The Greene vasomotor score after HT discontinuation. During the first 3 months after HT discontinuation, women that stopped HT abruptly (group 1) experienced significantly more severe vasomotor symptoms than those who ceased HT gradually (group 2) (P = 0.0001 and 0.001 at 1 and 3 months, respectively). Intriguingly, 6 months after HT discontinuation a switch of this trend was observed, where the severity of hot flushes and night sweats was significantly higher in group 2 (P = 0.001). The vasomotor score at 6 and 9 months after gradual discontinuation HT, when women in that group had been completely off HT for 1 and 3 months, was similar to that observed at 1 and 3 months in women who had abruptly stopped HT (4.31 and 3.75 versus 3.42 and 3.33, P = 0.073 and 0.24, respectively). Gradual cessation of HT by day tapering for 3 months (half-dosing of HT) resulted in a moderate elevation of the vasomotor score (0.65 versus 1.74, P = 0.003). Beyond that period, for the next 3 months, the vasomotor score raised dramatically (1.74 versus 4.3, P G 0.0001).
FIG. 4. The Greene mood score after HT discontinuation. Mood disturbances were significantly worse 1 month after HT withdrawal in the group that ceased HT abruptly (P = 0.049). However, by 3 months no significant differences could be recorded between groups.
FIG. 5. The Greene somatic score after HT discontinuation. The somatic symptomatology was significantly worse 1 month after HT withdrawal in the group that ceased HT abruptly (P = 0.022). However, by 3 months no significant differences were noted between groups.
whereas this was the major parameter for discontinuing HT during short-term use. 6 Weight gain and urogenital atrophy were cited by 30% of women after either method of HT discontinuation. Unexpectedly, both symptoms were reported early, beginning the first month after abrupt cessation of HT and along the process of gradually tapering HT. Weight and vaginal pH measurements were beyond the scope of this study, but these observations call for further investigation. Surprisingly, upon either abrupt or gradual cessation of HT, vaginal bleeding was not commonly reported. This may be due to an already thin endometrium after prolonged HT.
Our observations demonstrate for the first time that the severity of the reappearing climacteric symptoms after gradual HT discontinuation was not lower compared with that experienced after an abrupt withdrawal of therapy. A similar vasomotor score was reported at 1 and 3 months after abrupt cessation and at 6 and 9 months after a gradual tapering of HT, deferring the hypothesis of an adaptation effect after gradual discontinuation of HT. Our results support the data from two recent retrospective studies suggesting that tapering HT, rather than stopping it abruptly, reduce neither the recurrence of menopause symptoms 13 nor the proportion of patients who resumed HT. 13, 14 Gradual discontinuation of HT did not confer in our study any adaptive effect that led to a better climacteric symptomatology profile. Conversely, these results support an alternative hypothesis advocating that once an estrogen threshold level is reached, vasomotor, mood, and sexual disturbances reappear. Recently, a new theory has been proposed corroborating the concept of an individualized estrogen threshold, below which vasomotor symptoms reappear irrespective of the rate of decline in estrogen levels. A central mechanism was asserted to be responsible for small core body temperature (Tc) elevations that precede menopause hot flushes. It was claimed that the thermoneutral zone was virtually nonexistent in women with hot flushes, and that a small increase in Tc, acting within a narrowed thermoneutral zone, triggers a hot flush. It was suggested that estrogen, through an effect on the hypothalamic thermoregulatory center, broadens the thermoneutral zone. 11 Along with the NAMS recommendation of minimizing the HT dose, our study shows that tapering HT for the first 3 months resulted in a moderate elevation of the vasomotor score (0.65 versus 1.74, P = 0.003); however, with continued HT tapering for the next 3 months, the vasomotor score raised dramatically (1.74 versus 4.3, P G 0.0001; Fig. 6 ). This observation supports the NAMS recommendation of individual adjustment and reduction of the HT dose at the cost of slight vasomotor discomfort. This trend may suggest acceptable vasomotor symptom tolerability with HT half-dosing.
This study had several weaknesses. It was a randomized, interventional, nonblinded study. Blinding the women to the method of discontinuation would have required the use of placebo tablets, which is technically a very difficult measure in clinical reality. The sample size was small and probably accounts for several group differences such as higher age (P = 0.008) and concern about breast cancer (P = 0.04) in the abrupt HT cessation group ( Table 1 ). The patient sample was mainly nonobese. Because obese women tend to have more pronounced vasomotor symptoms, the results may differ in such a group. Finally, estrogen serum levels were not measured during the study to rule out group differences as a confounding factor. However, estrogen serum levels were never fully correlated with climacteric symptomatology.
CONCLUSIONS
The regimen of gradual HT discontinuation used in this study merely postponed, and neither prevented the reappearance nor attenuated the severity of vasomotor symptoms, mood deterioration, and sexual dysfunction. Nevertheless, gradual withdrawal from HT has some important advantages over the Bcold turkey^method. With the concept of minimizing HT dose in mind, the gradual tapering of therapy enables the patient to titrate down the dose until climacteric symptoms reappear to such an extent that a functional disruption of life ensues. Identification of the individual threshold estrogen level of climacteric symptoms would enable one to treat a patient with the smallest dose required for the control of the climacteric symptoms.
